Recruiting

GORE® ENFORM

Sponsor:

W.L.Gore & Associates

Code:

NCT04718168

Conditions

Hernia, Ventral

Hernia, Hiatal

Hernia, Diaphragmatic

Incisional Hernia

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Gore ENFORM Biomaterial (Preperitoneal)

Gore ENFORM Biomaterial (Intraperitoneal)

Study Details

Brief summary:

A prospective, retrospective, non-randomized, multicenter study with two independent hernia study cohorts (Ventral / Incisional Hernia Repair and Diaphragmatic / Hiatal Hernia Repair). The primary objective of this study is to collect GORE® ENFORM Biomaterial product commercial-use data on device functional performance and short-term patient experience.

Conditions

Hernia, Ventral

Hernia, Hiatal

Hernia, Diaphragmatic

Incisional Hernia

Study ID

NCT04718168

Start date

May 17, 2021

Status verified date

Jul, 2026

Completion date

Sep, 2026

Anticipated

Primary completion date

Sep, 2026

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Pre-procedure Inclusion Criteria:

The subject is / has:

1. At least 18 years old at the time of informed consent. Minimum age required by state regulations (as applicable).
2. An expected scored Class I (Clean) surgical wound using CDC Surgical Wound Classification system.
3. A planned implant with GORE® ENFORM Biomaterial for a single site ventral or hiatal hernia repair as suture line reinforcement.
4. An expected scored Grade 1 or Grade 2 using the Ventral Hernia Working Group Grading system.
5. Willing to provide informed consent and comply with follow-up requirements.

Pre-procedure Exclusion Criteria:

The subject is / has:

1. Treated in another drug or medical device study within 1 year of study enrollment.
2. Implanted with GORE® ENFORM Biomaterial in the reconstruction of cardiovascular defects.
3. Hernia repair expected to be performed as part of a bridged procedure (i.e., expected inability to perform primary closure of fascia or crura, patients requiring permanent support from the device).
4. A BMI >40.
5. Evidence of a systemic infection.
6. Cirrhosis or undergoing dialysis.
7. A wound-healing disorder.
8. Immunocompromised such as, with HIV or transplant, or receiving chemo or radiation therapy.
9. Expected to undergo mesh implantation in conjunction with any bariatric procedure and / or panniculectomy procedure.
10. A stoma.
11. Co-morbid conditions that may limit their ability to comply with study and follow-up requirements.
12. Positive pregnancy or lactation status as confirmed by site standard of care.
13. Hernias requiring treatment within multiple body regions or expected use of multiple hernia mesh devices.

Post-procedure Inclusion Criteria

At the time of index procedure, the subject is / has:

1. At least 18 years old. Minimum age required by state regulations (as applicable).
2. Implanted with GORE® ENFORM Biomaterial for a single site ventral or hiatal hernia repair as suture-line reinforcement on or before 365 days prior to site protocol amendment 3 approval date.
3. Unless there is an Informed Consent waiver issued by the Institutional Review Board (IRB), an Informed Consent Form (ICF) signed by subject.

Post-procedure Exclusion Criteria

At the time of index procedure, the subject is / has:

1. Treated in another drug or medical device study within 1 year of study enrollment.
2. Implanted with GORE® ENFORM Biomaterial in the reconstruction of cardiovascular defects.
3. Hernia repair that was performed as part of a bridged procedure (i.e., inability to perform primary closure of fascia or crura, patients requiring permanent support from the device).
4. A BMI >40.
5. Evidence of a systemic infection.
6. Cirrhosis or undergoing dialysis.
7. A wound-healing disorder.
8. Immunocompromised such as, with HIV or transplant, or receiving chemo or radiation therapy.
9. Underwent mesh implantation in conjunction with any bariatric procedure and / or panniculectomy procedure.
10. A stoma.
11. Co-morbid conditions that may limit their ability to comply with study and follow-up requirements.
12. Positive pregnancy or lactation status as confirmed by site standard of care.
13. Hernias requiring treatment within multiple body regions or expected use of multiple hernia mesh devices.

Study Design

Enrollment

245 participants

Anticipated

Allocation

Non randomized

Intervention Model

Parallel Assignment

Primary purpose

Treatment

Interventions and Outcome Measures

Arms

experimental: Ventral/Incisional Hernia - Preperitoneal ENFORM Biomaterial

experimental: Ventral/Incisional Hernia - Intraperitoneal ENFORM Biomaterial

experimental: Hiatal/Diaphragmatic Hernia - Preperitoneal ENFORM Biomaterial

experimental: Hiatal/Diaphragmatic Hernia-Intraperitoneal ENFORM Biomaterial

Interventions

Gore ENFORM Biomaterial (Preperitoneal)

ENFORM Biomaterial bioabsorbable hernia mesh

Gore ENFORM Biomaterial (Intraperitoneal)

ENFORM Biomaterial bioabsorbable hernia mesh

Primary outcome measure

  • Hernia Recurrence - Primary Device Endpoint [ Time Frame: Through 24 months ]
  • Incidence of SSI - Primary Procedural Endpoint 1 [ Time Frame: First Post-Procedural Visit (Days 1-45) ]
  • Incidence of SSO - Primary Procedural Endpoint 2 [ Time Frame: First Post-Procedural Visit (Days 1-45) ]
  • Incidence of SSOPI - Primary Procedural Endpoint 3 [ Time Frame: First Post-Procedural Visit (Days 1-45) ]

Central Contacts and Locations

Central contacts

Heidie Hornstra O'Neill

443-907-3152hhornstr@wlgore.com

Locations

University of California - San Diego

Recruiting

San Diego, California, United States, 92093

Contacts

Principal Investigator:

Ryan Broderick, MD

Institute of Esophageal and Reflux Surgery

Recruiting

Denver, Colorado, United States, 80124

Principal Investigator:

Philip Woodworth, MD

Northshore University Health System Research Institute

Recruiting

Evanston, Illinois, United States, 60201

Contacts

Principal Investigator:

Michael Ujiki, MD

University of Kentucky

Recruiting

Lexington, Kentucky, United States, 40506

Contacts

Principal Investigator:

John Roth, MD

Prisma Health - Upstate

Recruiting

Greenville, South Carolina, United States, 29615

Contacts

Principal Investigator:

Jeremy Warren, MD

University of Texas Health Science Center at Houson

Recruiting

Houston, Texas, United States, 77401

Contacts

Principal Investigator:

Julie Holihan, MD

Medical College of Wisconsin

Recruiting

Milwaukee, Wisconsin, United States, 53226

Contacts

Krissa Packard, MS, ACRP-CP

414-955-1861kpackard@mcw.edu

Principal Investigator:

Matthew Goldblatt, MD

More Information

Sponsor

W.L.Gore & Associates

Last update posted

Jul 30, 2026

Last verified

Jul, 2026

Keywords

  • hernia
  • ventral
  • hiatal
  • diaphragmatic
  • incisional
  • mesh
  • Gore
  • W.L. Gore
  • Enform

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-08. This information was provided to ClinicalTrials.gov by W.L.Gore & Associates on 2026-07-30.